Pharmaceutical
Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Cosmetic Raw Material
OEM & ODM
Veterinary raw materials
Phone: 86-29-89601602
E-mail: sales28@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
Raw Materials powder Strontium ranelate
Product Overview:
Strontium ranilate has the dual pharmacological effects of inhibiting bone absorption and promoting bone formation. On the one hand, in osteoblast-enriched cells, collagen and non-collagen synthesis can be increased, and osteoblast-mediated bone formation can be promoted by enhancing the proliferation of preosteoblasts. On the other hand, by reducing osteoclast differentiation and reabsorption activity, bone resorption is reduced, and bone renewal is re-balanced, which is conducive to bone formation.
Raw Materials powder Strontium ranelate Attributes
CAS:135459-87-9
MF:C12H12N2O8SSr
MW:431.91
EINECS:690-882-9
Specification: 99% min Strontium ranelate powder
Sample:Strontium ranelate powder
Packaging:1kg/bag, 25kg/drum
Brand: Henrikang
Appearance:white
Storage: Cool Dry Place
Shelf Life: 2 Years
Test Method: HPLC
Raw Materials powder Strontium ranelate Details
Strontium ranelate powder Usage and Synthesis.
Strontium ranelate exerts its pharmacological effects mainly through the atoms of strontium, an alkaline earth metal that is in the same family as calcium and sits below calcium on the periodic table. Its absorption, distribution and excretion are similar to calcium. After 2g orally. The absolute bioavailability of strontium is 27%. High dose of strontium can cause abnormal bone mineral metabolism, low dose of strontium can enhance the replication of preosteoblasts, increase the number of osteoblasts, and stimulate bone formation. At the same time, it can also reduce the activity of osteoclasts, reduce the number of osteoclasts, and reduce the rate of bone absorption. Studies in animals and humans have also shown consistent results.
Osteoporosis (OP) is a progressive bone disease characterized by decreased bone density (BMD) and degenerative changes in the microstructure of bone tissue. It is characterized by increased bone fragility and fracture, the latter of which is most common in the spine, hip and wrist. Estrogen, which keeps bones strong, stops being produced after women stop menstruating or have their ovaries surgically removed. Therefore, primary OP is particularly common in postmenopausal or menopausal women.
At present, there are two kinds of drugs commonly used in the treatment of osteoporosis: one is to inhibit the activity of osteoclasts and thus inhibit bone resorption drugs, such as diphosphonate, estrogen, calcitonin, etc.; The second type of drugs is to promote the activity of osteoblasts and stimulate bone formation. At present, there is only one product of recombinant parathyroid hormone 1-34 on the market, which needs to be injected and has a high drug price.
Uses of Strontium ranelate.
It is mainly used to treat and prevent osteoporosis in postmenopausal women and significantly reduce the risk of vertebral fracture and hip fracture.
Pharmacological action of Strontium ranelate.
Product method of Bulk Strontium ranelate.
